Genetic Variations in Soluble Epoxide Hydrolase and Graft Function in Kidney Transplantation

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1353-1356

  Lee, S H ^a   Lee, J ^a   Cha, R ^a   Park, M H ^a   Ha, J W ^a   Kim, S ^a   Kim, Y S ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GUANINE; PROTEIN EPHX2;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CHI SQUARE TEST; CONFIDENCE INTERVAL; EPHX2 GENE; EXON; FEMALE; FOLLOW UP; GENE; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RENAL GRAFT DYSFUNCTION; RENAL PROTECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; ADULT; ARACHIDONIC ACIDS; EPOXIDE HYDROLASES; EXONS; FOLLOW-UP STUDIES; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 45449115752     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.137     Document Type: Article

References (25)

1. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378
2. Reinders M.E., Rabelink T.J., and Briscoe D.M. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 17 (2006) 932
3. Moncada S., Palmer R.M., and Higgs E.A. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 12 (1988) 365
4. Furchgott R.F., and Vanhoutte P.M. Endothelium-derived relaxing and contracting factors. Faseb J 3 (1989) 2007
5. Imig J.D., Navar L.G., Roman R.J., et al. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7 (1996) 2364
6. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82 (2002) 131
7. Przybyla-Zawislak B.D., Srivastava P.K., Vazquez-Matias J., et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 64 (2003) 482
8. Srivastava P.K., Sharma V.K., Kalonia D.S., et al. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch Biochem Biophys 427 (2004) 164
9. Lee C.R., North K.E., Bray M.S., et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15 (2006) 1640
10. Fornage M., Lee C.R., Doris P.A., et al. The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. Hum Mol Genet 14 (2005) 2829
11. Anglicheau D., Verstuyft C., Laurent-Puig P., et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14 (2003) 1889
12. Hueso M., Navarro E., Moreso F., et al. Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation 81 (2006) 1463
13. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948
14. Morris S.T., McMurray J.J., Rodger R.S., et al. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 57 (2000) 1100
15. Landray M.J., Wheeler D.C., Lip G.Y., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the Chronic Renal Impairment in Birmingham (CRIB) study. Am J Kidney Dis 43 (2004) 244
16. Sinal C.J., Miyata M., Tohkin M., et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275 (2000) 40504
17. Zhao X., Yamamoto T., Newman J.W., et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15 (2004) 1244
18. Larsson C., White I., Johansson C., et al. Localization of the human soluble epoxide hydrolase gene (EPHX2) to chromosomal region 8p21-p12. Hum Genet 95 (1995) 356
19. Sandberg M., and Meijer J. Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). Biochem Biophys Res Commun 221 (1996) 333
20. Yoshimura K., Hanaoka T., Ohnami S., et al. Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 48 (2003) 654
21. Fornage M., Boerwinkle E., Doris P.A., et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109 (2004) 335
22. de M.C.H., Meijer H., and Lissenden S. Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin Cell Dev Biol 16 (2005) 49
23. Mazumder B., Seshadri V., and Fox P.L. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci 28 (2003) 91
24. Hariharan S., McBride M.A., and Cohen E.P. Evolution of endpoints for renal transplant outcome. Am J Transplant 3 (2003) 933
25. Gorodetskaya I., Zenios S., McCulloch C.E., et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 68 (2005) 2801